Samenvatting
Samenvatting Immunologie
- Vak
- Immunologie
- Instelling
- Katholieke Universiteit Leuven (KU Leuven)
Dit document bevat samenvatting van de slides, gegeven door prof. Vanaudenaerde en prof. Sprangers
[Meer zien]Voorbeeld 10 van de 157 pagina's
Voorbeeld 10 van de 157 pagina's
In winkelwagen
Voorbeeld van de inhoud
INHOUDHoofdstuk 1: het immuunsysteem.................................................................................................................................1
Inleiding .......................................................................................................................................................................1
Belangrijke concepten van het humane immuunsysteem.......................................................................................1
Innate immuunsysteem ..........................................................................................................................................1
Adaptief immuunsysteem ......................................................................................................................................2
Primaire immuunrespons ...................................................................................................................................2
Secundaire immuunrespons ..............................................................................................................................2
Klonale selectie .......................................................................................................................................................2
The good, the bad and the ugly van het immuunsysteem.......................................................................................3
Dysfuncties ..............................................................................................................................................................3
Transplantatie .........................................................................................................................................................3
Kanker ......................................................................................................................................................................3
Tolerantie.................................................................................................................................................................3
Hoofdstuk 2: cellen, organen en omgeving van het immuunsysteem ........................................................................4
Cellen van het immuunsysteem.................................................................................................................................4
Common myeloïde progenitor...............................................................................................................................4
Erythrocyten (RBC)..............................................................................................................................................4
Monocyten ..........................................................................................................................................................4
Granulocyten.......................................................................................................................................................5
Megakaryocyten (BP) .........................................................................................................................................7
Common lymphoid progenitor...............................................................................................................................7
B-lymfocyten .......................................................................................................................................................7
T-lymfocyten .......................................................................................................................................................8
Natural killer cellen (NK-cellen) .........................................................................................................................8
Diagnostische technieken...........................................................................................................................................8
Perifeer bloeduitstrijkje..........................................................................................................................................8
Hematoxyline-eosine (H&E)...............................................................................................................................8
May-Grünwald Giemsa (MGG)...........................................................................................................................8
Flowcytometrie .......................................................................................................................................................9
Primaire lymfoïde organen.........................................................................................................................................9
Beenmerg ................................................................................................................................................................9
Thymus.................................................................................................................................................................. 11
Secundaire lymfoïde organen ................................................................................................................................. 13
Lymfeknopen........................................................................................................................................................ 13
Milt ........................................................................................................................................................................ 15
, Mucosa-associated lymphoid tissue (MALT)...................................................................................................... 15
Barrière organen ...................................................................................................................................................... 16
Hoofdstuk 3: herkenning en respons .......................................................................................................................... 17
Signaaltransductie.................................................................................................................................................... 17
Definities............................................................................................................................................................... 17
Ligand-receptor binding ...................................................................................................................................... 17
Antigen-receptor binding ................................................................................................................................ 18
Combinatie receptoreiwitten.......................................................................................................................... 18
Proces.................................................................................................................................................................... 18
Lipid rafts en R-multimerisatie........................................................................................................................ 18
Fosforylatie tyrosine-residu’s.......................................................................................................................... 19
Intracellulaire adapter-eiwitten...................................................................................................................... 19
Gemeenschappelijk downstream pathways .................................................................................................. 20
Receptoren in immuunsysteem .............................................................................................................................. 20
Immunoglobuline superfamilie (adaptive)......................................................................................................... 20
B-cel receptor (BCR) (antistoffen – immunoglobulines) ............................................................................... 21
Structuur ...................................................................................................................................................... 21
Antigen-herkenning..................................................................................................................................... 22
Isotypes ........................................................................................................................................................ 22
BCR-complex ................................................................................................................................................ 23
T-cel receptor (TCR) (adaptive)....................................................................................................................... 23
Structuur ...................................................................................................................................................... 23
TCR-complex ................................................................................................................................................ 24
Pattern recognition receptoren (PRR) (innate) .................................................................................................. 24
Complement receptoren (innate) en Fc-receptoren......................................................................................... 24
Cytokine receptoren (innate) .............................................................................................................................. 25
Werking ............................................................................................................................................................ 25
6 superfamilies ................................................................................................................................................. 26
Interleukine-1 (IL-1) familie ........................................................................................................................ 26
Hematopoïetine famillie (klasse 1)............................................................................................................. 27
Interferon familie (klasse 2)........................................................................................................................ 28
Tumor necrosis factor (TNF) familie........................................................................................................... 28
Interleukine-17 (IL-17) familie .................................................................................................................... 29
Chemokine familie....................................................................................................................................... 30
Hoofdstuk 4: innate immuunsysteem......................................................................................................................... 31
Anatomische barrière tegen infectie ...................................................................................................................... 31
Epitheliale fysieke barrière.................................................................................................................................. 31
, Epitheliale chemische barrière............................................................................................................................ 31
Cellulaire innate immuunrespons ........................................................................................................................... 31
Toll-like receptor (TLR)......................................................................................................................................... 32
C-type lectin receptor (CLR) ................................................................................................................................ 33
NOD-like receptor (NLR) ...................................................................................................................................... 33
RIG-I-like receptor (RLR) ...................................................................................................................................... 33
AIM2-like receptor (ALR) ..................................................................................................................................... 33
cGAS en STING...................................................................................................................................................... 34
Effector innate immuunrespons ............................................................................................................................. 34
Expressie van innate immuunsysteem eiwitten ................................................................................................ 34
Fagocytose............................................................................................................................................................ 35
Opsonisatie....................................................................................................................................................... 36
Gecontroleerde celdood...................................................................................................................................... 37
Inflammatoire respons ........................................................................................................................................ 37
Innate lymfoïde cellen (ILC)............................................................................................................................. 38
Natural killer cellen (NK) ............................................................................................................................. 39
Lymphoid tissue inducer cells (LTi)............................................................................................................. 39
Regulatie innate en inflammatoire respons ........................................................................................................... 39
Interactie tussen innate en adaptief immuunsysteem ......................................................................................... 40
Hoofdstuk 5: complement systeem ............................................................................................................................ 41
Klassieke pathway .................................................................................................................................................... 42
Lectine of mannose-binding lectine (MBL) pathway ............................................................................................. 42
Alternatieve pathway .............................................................................................................................................. 43
Thick-over pathway.............................................................................................................................................. 43
Properdine-geactiveerde pathway ..................................................................................................................... 43
Protease-geactiveerde pathway ......................................................................................................................... 44
Functies complementsysteem ................................................................................................................................ 44
Connectie complement-tagged pathogenen en effectorcellen........................................................................ 45
Versterking gastheer-verdediging tegen infecties............................................................................................. 45
Situeren op interface innate en adaptief immuunsysteem .............................................................................. 45
Actief in contractiefase van immuunrespons .................................................................................................... 46
Regulatie complementsysteem............................................................................................................................... 46
Complement-deficiënties .................................................................................................................................... 47
Microbiële strategieën om complementsysteem te omzeilen ......................................................................... 47
Hoofdstuk 6: organisatie en expressie van lymfocyte receptor genen .................................................................... 48
Immunoglobulines (Ig) genen ................................................................................................................................. 48
Inleiding ................................................................................................................................................................ 48
, Multigene organisatie.......................................................................................................................................... 48
κ-lichte keten.................................................................................................................................................... 48
λ-lichte keten.................................................................................................................................................... 48
Zware keten...................................................................................................................................................... 48
Mechanisme van V(D)J-recombinatie................................................................................................................. 49
Betrokken eiwitten .......................................................................................................................................... 49
Recombination-signaal sequenties (RSSs) ................................................................................................. 50
Recombination activating gene (RAG) 1/2 ................................................................................................ 51
Proces ............................................................................................................................................................... 51
Regulatie........................................................................................................................................................... 52
Intranucleaire localisatie van antigen receptor chromatine............................................................................. 52
Allelic exclusion .................................................................................................................................................... 52
B-cel receptor (BCR)................................................................................................................................................. 53
Autoreactieve BCR ............................................................................................................................................... 53
Expressie B-cel receptor (BCR) ............................................................................................................................ 53
T-cel receptor (TCR) ................................................................................................................................................. 53
Genen en expressie.............................................................................................................................................. 53
Vergelijking mechanismen voor vorming en expressie BCR of TCR ..................................................................... 54
Hoofdstuk 7: major histocompatibility complex (MHC) en antigenpresentatie...................................................... 55
Structuur en functie van MHC-moleculen.............................................................................................................. 55
MHC klasse I molecule......................................................................................................................................... 55
MHC-klasse II molecule........................................................................................................................................ 55
Peptide-binding aan MHC klasse I en II moleculen............................................................................................ 56
Organisatie en overerving van MHC....................................................................................................................... 56
Rol en expressie van MHC ....................................................................................................................................... 56
MHC I-moleculen presenteren intracellulaire antigen peptiden...................................................................... 57
MHC II-moleculen presenteren zowel intracellulaire als extracellulaire antigen peptiden ........................... 57
Types antigen-presenterende cellen (APC)........................................................................................................ 57
Antigen-processing pathway ............................................................................................................................... 57
Endogene pathway van antigen processing en presentatie......................................................................... 57
Exogene pathway van antigen processing en presentatie ........................................................................... 58
Cross-presentatie van exogene antigenen ................................................................................................ 59
Presentatie van niet-peptide antigenen .................................................................................................... 59
Hoofdstuk 8: T-cel ontwikkeling.................................................................................................................................. 60
Ontwikkeling T-cellen in thymus ............................................................................................................................. 60
Vroege thymocyte ontwikkeling ......................................................................................................................... 60
Positieve en negatieve selectie....................................................................................................................... 61
, Lineage commitment....................................................................................................................................... 62
Verlaten thymus en finale maturatie.................................................................................................................. 63
Mechanismen om zelf-tolerantie te behouden ..................................................................................................... 63
Hoofdstuk 9: B-cel ontwikkeling.................................................................................................................................. 64
Plaats hematopoïese................................................................................................................................................ 64
Ontwikkeling B-cellen in beenmerg........................................................................................................................ 64
Stadia hematopoïese ........................................................................................................................................... 64
Ontwikkeling B-1 B-cellen en marginale zone B-cellen ..................................................................................... 66
Vergelijking B-cel en T-cel ontwikkeling................................................................................................................. 66
Hoofdstuk 10: T-cel activatie, helper subset differentiatie en geheugen ................................................................ 68
T-cel activatie: 2-signaal-hypothese ....................................................................................................................... 68
Co-stimulatoire signalen..................................................................................................................................... 69
Immunologische synaps .................................................................................................................................. 69
Positieve co-stimulatoire signalen.................................................................................................................. 70
Proces.................................................................................................................................................................... 71
T-cel activatie: APC................................................................................................................................................... 71
T-cel activatie: superantigenen............................................................................................................................... 72
T-cel differentiatie.................................................................................................................................................... 72
Co-stimulatoire signalen...................................................................................................................................... 72
Cytokines .......................................................................................................................................................... 72
Helper T-cellen subsets........................................................................................................................................ 73
TH1/TH2 cross regulatie.................................................................................................................................... 74
TH17/TREG cross regulatie ................................................................................................................................. 75
TFH-cellen .......................................................................................................................................................... 76
TH9-cellen.......................................................................................................................................................... 76
TH22-cellen ....................................................................................................................................................... 76
T-cel differentiatie: TH cel plasticiteit ..................................................................................................................... 76
TH-cellen in gezondheid en ziekte ........................................................................................................................... 77
T-cel geheugen ......................................................................................................................................................... 77
Hoofdstuk 11: B-cel activatie, differentiatie en geheugen........................................................................................ 78
B-cel activatie: clonale selectie hypothese ............................................................................................................ 78
B-cel activatie: T depente B-cel reactie .................................................................................................................. 78
Immunologische synaps ...................................................................................................................................... 79
Ag-endocytose...................................................................................................................................................... 79
Chemokine geleide B-cel migratie ...................................................................................................................... 79
Vroege fase....................................................................................................................................................... 79
Verdere proliferatie en differentiatie B-cellen .............................................................................................. 79
, Plasmacellen ................................................................................................................................................ 80
Vorming germinale centra .......................................................................................................................... 80
Vroege geheugen B-cellen (IgM) ................................................................................................................ 81
Einde respons ................................................................................................................................................... 82
B-cel activatie: T indepente B-cel reactie (dia 109) ............................................................................................... 82
Respons................................................................................................................................................................. 82
B-1 B-cellen ...................................................................................................................................................... 82
Marginale zone B-cellen (B-2 B-cellen) .......................................................................................................... 83
Negatieve regulatie B-cellen ............................................................................................................................... 83
Hoofdstuk 12: effector respons................................................................................................................................... 84
Antistof-gemedieerde immuniteit .......................................................................................................................... 84
FCR ......................................................................................................................................................................... 84
FCγR.................................................................................................................................................................... 85
FcεR .................................................................................................................................................................... 85
FCαR ................................................................................................................................................................... 85
FCμR en FCα/μR .................................................................................................................................................. 86
Poly-IgR............................................................................................................................................................. 86
FCRn.................................................................................................................................................................... 86
IgM-Ab .................................................................................................................................................................. 86
IgG-Ab ................................................................................................................................................................... 86
IgA-Ab.................................................................................................................................................................... 87
IgE-Ab .................................................................................................................................................................... 87
IgD-Ab ................................................................................................................................................................... 87
Cel-gemedieerde immuniteit .................................................................................................................................. 87
Cytotoxische T-lymfocyten (CTL) cellen.............................................................................................................. 87
TCR-activatie .................................................................................................................................................... 88
Killing-mechanisme CTL-cellen ....................................................................................................................... 88
NKT-cellen............................................................................................................................................................. 89
NK-cellen............................................................................................................................................................... 89
Receptoren ....................................................................................................................................................... 89
Missing self-model........................................................................................................................................... 90
Licensing en regulering ........................................................................................................................................ 90
Hoofdstuk 13: barrière-immuniteit............................................................................................................................. 91
Barrière-immuniteit ................................................................................................................................................. 91
Intestinale immuniteit ............................................................................................................................................. 92
Cellen .................................................................................................................................................................... 92
Barrièrefunctie ..................................................................................................................................................... 92
, Ag-APC interactie ................................................................................................................................................. 93
Immuunhomeostase............................................................................................................................................ 93
Cytokines .......................................................................................................................................................... 94
Mechanisme..................................................................................................................................................... 94
Commensale flora ................................................................................................................................................ 95
Respons op ziekteverwekkers ............................................................................................................................. 95
Respiratoir immuunsysteem ................................................................................................................................... 97
Huid........................................................................................................................................................................... 98
Hoofdstuk 14: adaptieve immuunrespons in tijd en ruimte ..................................................................................... 99
Homeostase: gedrag van immuuncellen voor ze in contact komen met Ag ....................................................... 99
Immuunrespons bij contact met Ag ..................................................................................................................... 100
Aangeboren (innate) immuunrespons ............................................................................................................. 100
Adaptive immuunrespons ................................................................................................................................. 101
Effector en geheugen immuunrespons ............................................................................................................ 102
Voorbeelden........................................................................................................................................................... 102
Hoofdstuk 15: allergie, hypersensitiviteit en chronische inflammatie ................................................................... 103
Hypersensitiviteitsreactie...................................................................................................................................... 103
Type-I hypersensitiviteitsreactie (allergie – IgE) .............................................................................................. 103
Mediatoren..................................................................................................................................................... 104
Histamine ................................................................................................................................................... 104
Leukotriënen en prostaglandines ............................................................................................................. 104
Cytokines en chemokines.......................................................................................................................... 105
Fasen............................................................................................................................................................... 105
Categorieën .................................................................................................................................................... 105
Systemische anafylaxie ............................................................................................................................. 105
Gelokaliseerde overgevoeligheidsreactie................................................................................................ 105
Voedselallergieën ...................................................................................................................................... 106
Omgevingsfactoren........................................................................................................................................ 106
Diagnostische test.......................................................................................................................................... 107
Behandelingen ............................................................................................................................................... 107
Type-II hypersensitiviteitsreactie (antistof-gemedieerd – IgM, IgG).............................................................. 107
Transfusiereacties (ABO-incompatibiliteit).................................................................................................. 107
Type-III hypersensitiviteitsreactie (immuuncomplexen)................................................................................. 108
Type-IV hypersensitiviteitsreactie (cel) ............................................................................................................ 109
Sensibilisatie fase........................................................................................................................................... 109
Effector fase ................................................................................................................................................... 109
Diagnostische test.......................................................................................................................................... 109
, Contactdermatitis .......................................................................................................................................... 110
Chronische inflammatie......................................................................................................................................... 110
Infectieuze oorzaken.......................................................................................................................................... 110
Niet-infectieuze oorzaken ................................................................................................................................. 110
Hoofdstuk 16: tolerantie, auto-immuniteit, transplantatie .................................................................................... 112
Tolerantie................................................................................................................................................................ 112
Antigeen-sequestratie ....................................................................................................................................... 112
Centrale tolerantie............................................................................................................................................. 112
Perifere tolerantie.............................................................................................................................................. 112
Regulatoire CD4 T-cellen (CD4 TREG) ............................................................................................................. 113
Regulatoire CD8 T-cellen (CD8 TREG) ............................................................................................................. 113
Regulatoire B-cellen (BREG) ............................................................................................................................ 113
Myeloïd-derived suppressor cells (MDSC) ................................................................................................... 113
Auto-immuniteit..................................................................................................................................................... 114
Orgaanspecifieke auto-immuniteit................................................................................................................... 115
Systemische auto-immuniteit ........................................................................................................................... 115
Gevoeligheid voor auto-immuunziekten.......................................................................................................... 116
Behandeling........................................................................................................................................................ 117
Breedspectrum therapie ............................................................................................................................... 117
Therapie gericht op specifieke celtypen of pathways................................................................................. 117
Therapie gericht op blokkeren ontstekingsproces ...................................................................................... 117
Therapie gericht op interferentie met co-stimulatie .................................................................................. 118
Antigeen-specifieke immunotherapie.......................................................................................................... 118
Transplantatie ........................................................................................................................................................ 118
Afstoting (rejectie) ............................................................................................................................................. 118
Mate en type van immuunrespons .............................................................................................................. 118
Specificiteit en geheugen bij afstoten allograft ........................................................................................... 118
Sommige organen meer geschikt dan andere voor klinische transplantatie ............................................ 118
Klinisch verloop.............................................................................................................................................. 119
Immunosuppressieve therapie ..................................................................................................................... 119
Hoofdstuk 17: infectieuze ziekten en vaccinatie...................................................................................................... 121
Belang van barrière-immuniteit en innate immuunsysteem.............................................................................. 121
Slijmvlies- of barrière-infecties worden onder controle gehouden door T H2-type immuunreacties .......... 121
Extracellulaire pathogenen moeten herkend worden en aangevallen mbv extracellulaire hulpmiddelen 121
Mechanisme die geïnfecteerde gastheercellen herkennen, zijn nodig om intracellulaire infecties te
bestrijden............................................................................................................................................................ 121
Virale infecties........................................................................................................................................................ 122
, Aangeboren immuunrespons............................................................................................................................ 122
Adaptieve immuunrespons ............................................................................................................................... 122
Geheugenrespons .............................................................................................................................................. 123
Influenza ......................................................................................................................................................... 123
Bacteriële infecties................................................................................................................................................. 124
Tuberculose ........................................................................................................................................................ 124
Difterie ................................................................................................................................................................ 125
Parasitaire infecties................................................................................................................................................ 125
Malaria................................................................................................................................................................ 125
Afrikaanse slaapziekte ....................................................................................................................................... 125
Leishmaniasis...................................................................................................................................................... 125
Ziekten door parasitaire wormen ..................................................................................................................... 125
Schimmelinfecties .................................................................................................................................................. 126
Aangeboren immuniteit .................................................................................................................................... 126
Adaptieve immuniteit ........................................................................................................................................ 127
Emerging en re-emerging infecties....................................................................................................................... 127
Vaccinatie ............................................................................................................................................................... 127
Immunisatie........................................................................................................................................................ 127
Passieve immunisatie .................................................................................................................................... 127
Actieve immunisatie ...................................................................................................................................... 128
Vaccinatiestrategieën ........................................................................................................................................ 128
Levende, verzwakte vaccins .......................................................................................................................... 128
Geïnactiveerde of gedoode vaccins.............................................................................................................. 128
Subeenheid vaccins ....................................................................................................................................... 129
Recombinante vectorvaccins ........................................................................................................................ 129
DNA-vaccins.................................................................................................................................................... 129
RNA-vaccins.................................................................................................................................................... 130
Geconjugeerde of multivalente vaccins ........................................................................................................... 130
Adjuvantia........................................................................................................................................................... 130
Hoofdstuk 18: immuundeficiënties........................................................................................................................... 131
Primaire immuundeficiënties (PID)....................................................................................................................... 131
Onderliggende genetische afwijkingen ............................................................................................................ 131
Combined immunodeficiënties (CID) ........................................................................................................... 132
B-cel immuundeficiënties.............................................................................................................................. 134
Innate-immuundeficiënties (IS) .................................................................................................................... 135
Complement-deficiënties (immuun-regulatie) ............................................................................................ 135
NK-cellen-deficiënties.................................................................................................................................... 136
, Auto-immuun deficiënties............................................................................................................................. 136
Behandeling........................................................................................................................................................ 136
Secundaire immuundeficiënties ........................................................................................................................... 137
HIV....................................................................................................................................................................... 137
Rol van co-receptoren ................................................................................................................................... 139
Ziektestadia .................................................................................................................................................... 139
Behandeling.................................................................................................................................................... 140
Vaccinatie ....................................................................................................................................................... 140
Hoofdstuk 19: kanker en immuunsysteem............................................................................................................... 141
Inleiding .................................................................................................................................................................. 141
Kanker-geassocieerde genen ................................................................................................................................ 141
Maligne transformatie van cellen ......................................................................................................................... 142
Oncogenen ......................................................................................................................................................... 142
Tumorsuppressorgenen..................................................................................................................................... 143
Apoptotische genen........................................................................................................................................... 143
Tumor-antigenen ................................................................................................................................................... 144
Tumor-specifieke antigenen (TSA).................................................................................................................... 144
Tumor-geassocieerde antigenen (TAA) ............................................................................................................ 144
Immuunrespons tov kanker .................................................................................................................................. 144
Aangeboren inhibitoren .................................................................................................................................... 145
Adaptief immuunsysteem ................................................................................................................................. 145
Rol van cytokines................................................................................................................................................ 145
Factoren die immuunrespons beïnvloeden ..................................................................................................... 145
Chronische ontsteking................................................................................................................................... 145
Anti-tumor-versterkende antilichamen ....................................................................................................... 146
Actieve immunosuppressie ........................................................................................................................... 146
Factoren die immuunrespons ontwijken ......................................................................................................... 146
Verminderde MHC-expressie........................................................................................................................ 146
Resistentie tumorcellen tov apoptose-signalen .......................................................................................... 146
Slechte co-stimulatie door tumorcellen....................................................................................................... 146
Immuuntherapie .................................................................................................................................................... 146
Monoklonale antilichamen................................................................................................................................ 146
Celtherapie ......................................................................................................................................................... 147
Tumor-specifieke T-cellen ............................................................................................................................. 147
CAR-T-cellen ................................................................................................................................................... 147
Vaccins ................................................................................................................................................................ 147
Co-stimulatie ...................................................................................................................................................... 147
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
√ Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, Bancontact of creditcard voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper zGNK. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €13,49. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 80796 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen